Dimerix (ASX:DXB) ROE % Adjusted to Book Value : -6.78% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Dimerix ROE % Adjusted to Book Value?

Dimerix's ROE % for the quarter that ended in Dec. 2023 was -347.55%. Dimerix's PB Ratio for the quarter that ended in Dec. 2023 was 51.25. Dimerix's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -6.78%.

Dimerix ROE % Adjusted to Book Value Historical Data

The historical data trend for Dimerix's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dimerix ROE % Adjusted to Book Value Chart

Dimerix Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-16.26

-8.52

-5.05

-49.27

-32.79

Dimerix Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-30.25	-18.29	-20.99	-37.57	-6.78

Competitive Comparison of Dimerix's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Dimerix's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dimerix's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dimerix's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Dimerix's ROE % Adjusted to Book Value falls into.

Dimerix ROE % Adjusted to Book Value Calculation

Dimerix's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-135.42%	/	4.13
	=	-32.79%

Dimerix's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-347.55%	/	51.25
	=	-6.78%

Dimerix ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Dimerix's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Dimerix (ASX:DXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dimerix Ltd (ASX:DXB) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

425 Smith Street, Fitzroy, VIC, AUS, 3065

Website

https://www.dimerix.com

Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Dimerix (ASX:DXB) Headlines

No Headlines